Form 4: Tandem Diabetes Care Executive Granted Significant Equity Awards Under Long-Term Incentive Plan

Tandem Diabetes Care's EVP, Chief Strategy Officer, Elizabeth Anne Gasser, was granted 23,000 Performance Stock Units and 23,002 Restricted Stock Units as part of the company's 2023 Long-Term Incentive Plan.

Summary

• Elizabeth Anne Gasser, EVP, Chief Strategy Officer of Tandem Diabetes Care Inc. (TNDM), reported new equity awards on May 30, 2025.
• Ms. Gasser was granted 23,000 Performance Stock Units (PSUs), which are contingent rights to receive shares based on pre-defined performance metrics by December 31, 2027.
• The number of shares issued for PSUs may range from 0% to 200% of the awarded amount, depending on the company's actual performance relative to the metrics and Ms. Gasser's continued service.
• Additionally, 23,002 Restricted Stock Units (RSUs) were granted, with 33% vesting on May 15, 2026, and the remaining shares vesting in eight equal quarterly installments thereafter.
• These awards were made pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended.
• Ms. Gasser also beneficially owns 22,949 shares of common stock indirectly through The Gasser Family Trust dated September 1, 2011, of which she is a co-trustee.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally positive as it aligns management's interests with long-term shareholder value and aids in executive retention. The performance-based nature of a portion of the awards further strengthens this alignment.

Positives

• The grant of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) aligns executive compensation with company performance and long-term shareholder interests.
• The awards are part of the company's 2023 Long-Term Incentive Plan, indicating a structured and ongoing approach to executive compensation and retention.
• PSUs incentivize the achievement of specific pre-defined performance metrics, potentially driving strong future results and strategic execution.

Risks

• Performance Stock Units (PSUs) are contingent on achieving pre-defined performance metrics; if minimum metrics are not met by December 31, 2027, no PSUs will vest, potentially impacting executive compensation.
• Vesting of both PSUs and RSUs is subject to the awardee's continuing service through the respective vesting and measurement dates, posing a retention risk if the executive departs before these dates.

Future Outlook

The equity grants, particularly the Performance Stock Units, are tied to the achievement of pre-defined performance metrics by December 31, 2027, indicating a focus on future company performance. The Restricted Stock Units have a multi-year vesting schedule, extending through quarterly installments after May 15, 2026, which aims to retain the executive and align her interests with long-term shareholder value.

Industry Context

This Form 4 filing reflects a standard practice in the medical device and technology sectors, where long-term incentive plans, including performance and restricted stock units, are commonly used to attract, retain, and motivate key executives. Such compensation structures are designed to align executive interests with the company's strategic goals and shareholder returns, a prevalent trend across industries focused on innovation and growth.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) as part of an executive compensation package is a common and widely accepted practice within the medical technology and broader corporate landscape.
• Companies like Medtronic (MDT), Dexcom (DXCM), and Insulet (PODD), which operate in similar or related healthcare technology spaces, frequently utilize similar equity-based incentive programs to align executive performance with long-term shareholder value.
• The structure, including multi-year vesting for RSUs and performance-based metrics for PSUs, is consistent with best practices aimed at executive retention and incentivizing strategic achievements.

Corporate Governance

Related Party Transactions

• 22,949 shares of common stock are held indirectly by The Gasser Family Trust dated September 1, 2011, of which Elizabeth A. Gasser is a co-trustee.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.

Next Steps

• Achievement of pre-defined performance metrics for PSUs by December 31, 2027.
• Vesting of RSUs, with the first tranche on May 15, 2026, followed by eight equal quarterly installments.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Equity Grant, Performance Stock Units, Restricted Stock Units, Executive Compensation, Long-Term Incentive Plan, Beneficial Ownership